What is the clinical evidence from this study?

Study design: Other. Intervention: MyoD and myogenin overexpression vs. Control vector / no overexpression. Primary outcome: Transcriptional activation of cTnC enhancer (CAT activity).

What question did this study set out to answer?

This research aims to explore the regulatory elements controlling the cTnC gene during muscle differentiation.

March 1, 1994Molecular and Cellular Biology

A Novel Myogenic Regulatory Circuit Controls Slow/Cardiac Troponin C Gene Transcription in Skeletal Muscle

View Full Paper

Ask AI

Bookmark

Key result

The slow/cardiac troponin C gene contains a skeletal myotube-specific transcriptional enhancer in its first intron that is indirectly transactivated by myogenic bHLH proteins MyoD and myogenin.

Population

C3H10T1/2 (10T1/2) cells, myoblasts, and myotubes

Design

Preclinical

Authors

MPMichael S. ParmacekGeneral / Preventive / Lipids HIHon S. IpUnited States Geological Survey FJFrank JungUniversity Hospital of Zurich

Discussion

Member takes

Implication

No immediate clinical impact; extends cTnC transcriptional models and leaves open disease applications.

Key Points

This research aims to explore the regulatory elements controlling the cTnC gene during muscle differentiation.
Identified transcriptional enhancers in the cTnC gene using electrophoretic mobility shift assays.
Analyzed the effects of bHLH proteins MyoD and myogenin on gene expression in C3H10T1/2 cells.
Examined binding sites within the cTnC enhancer through cellular differentiation processes.
A second transcriptional enhancer located in the first intron of cTnC was identified, specific to skeletal myotubes.
Binding activity for MEF-2 was significantly up-regulated during myotube differentiation.
bHLH proteins were shown to transactivate the cTnC enhancer through indirect mechanisms.

Structured PICO

Population

C3H10T1/2 (10T1/2) cells, myoblasts, and myotubes

Intervention

Overexpression of myogenic bHLH proteins (MyoD and myogenin) / stable transfection with MyoD expression vector

Outcome

cTnC enhancer transactivation and changes in DNA binding activities (MEF-2, CACCC, and MEF-3)surrogate

The study identifies a novel skeletal myotube-specific enhancer in the first intron of the cTnC gene that is indirectly transactivated by bHLH transcription factors.

Cite This Study

Parmacek et al. (1994) studied this question. MyoD and myogenin overexpression vs. Control vector / no overexpression was evaluated on Transcriptional activation of cTnC enhancer (CAT activity). The slow/cardiac troponin C gene contains a skeletal myotube-specific transcriptional enhancer in its first intron that is indirectly transactivated by myogenic bHLH proteins MyoD and myogenin.

synapsesocial.com/papers/6a658fca1a73af1ea1b6a2d7 https://doi.org/10.1128/mcb.14.3.1870-1885.1994

View Full Paper

Ask AI

Bookmark

A Novel Myogenic Regulatory Circuit Controls Slow/Cardiac Troponin C Gene Transcription in Skeletal Muscle

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A Novel Myogenic Regulatory Circuit Controls Slow/Cardiac Troponin C Gene Transcription in Skeletal Muscle

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider